OBJECTIVE: Atypical meningiomas represent 20% of all meningiomas. This retrospective study analyzes the prognostic factors, the effect of different methods of treatments, and the behavior of atypical meningiomas. METHODS: The study comprised 44 patients who were given a diagnosis of atypical meningioma according to the 2007 World Health Organization classification in the period from January 2009 to March 2012. Data collected included patient age, gender, tumor location, presenting symptoms, and treatment received. Patients were followed to detect recurrence and assess survival. RESULTS: Median overall survival was 57 months, with a 5-year survival of 35%. Significantly better survival was observed for patients <50 years old (65 months vs. 46 months, P = 0.033) and patients with total resection (Simpson grade 1-2) compared with subtotal resection (Simpson grade 3-4) or biopsy (Simpson grade 5) (75 months vs. 46 months and 24 months, P < 0.0001). Patients with a tumor located in brain convexity had better survival but with no statistical significance (P = 0.052). Multivariate analysis showed prognostic significance with age (P = 0.030) and extent of resection (P < 0.000). Progression-free survival ranged from 7-83 months with a median of 39 months. Progression-free survival showed a significant relationship with subtotal resection compared with biopsy (P = 0.007). Recurrences were less in patients who received radiotherapy (RT), and this was statistically significant (P = 0.007). CONCLUSIONS: Long-term survival is possible for patients with atypical meningiomas treated with surgery and postoperative RT. Multivariate analysis confirmed that age (<50 years) and total surgical excision were independent prognostic factors for survival. Adjuvant RT reduces tumor recurrence, especially after incomplete surgery.
OBJECTIVE: Atypical meningiomas represent 20% of all meningiomas. This retrospective study analyzes the prognostic factors, the effect of different methods of treatments, and the behavior of atypical meningiomas. METHODS: The study comprised 44 patients who were given a diagnosis of atypical meningioma according to the 2007 World Health Organization classification in the period from January 2009 to March 2012. Data collected included patient age, gender, tumor location, presenting symptoms, and treatment received. Patients were followed to detect recurrence and assess survival. RESULTS: Median overall survival was 57 months, with a 5-year survival of 35%. Significantly better survival was observed for patients <50 years old (65 months vs. 46 months, P = 0.033) and patients with total resection (Simpson grade 1-2) compared with subtotal resection (Simpson grade 3-4) or biopsy (Simpson grade 5) (75 months vs. 46 months and 24 months, P < 0.0001). Patients with a tumor located in brain convexity had better survival but with no statistical significance (P = 0.052). Multivariate analysis showed prognostic significance with age (P = 0.030) and extent of resection (P < 0.000). Progression-free survival ranged from 7-83 months with a median of 39 months. Progression-free survival showed a significant relationship with subtotal resection compared with biopsy (P = 0.007). Recurrences were less in patients who received radiotherapy (RT), and this was statistically significant (P = 0.007). CONCLUSIONS: Long-term survival is possible for patients with atypical meningiomas treated with surgery and postoperative RT. Multivariate analysis confirmed that age (<50 years) and total surgical excision were independent prognostic factors for survival. Adjuvant RT reduces tumor recurrence, especially after incomplete surgery.
Authors: Ernest Barthélemy; Joshua Loewenstern; Neeraja Konuthula; Margaret Pain; Jordan Hall; Satish Govindaraj; Joshua Bederson; Raj K Shrivastava Journal: J Cancer Res Clin Oncol Date: 2018-03-02 Impact factor: 4.553
Authors: Akash J Patel; Ying-Wooi Wan; Rami Al-Ouran; Jean-Pierre Revelli; Maria F Cardenas; Mazen Oneissi; Liu Xi; Ali Jalali; John F Magnotti; Donna M Muzny; HarshaVardhan Doddapaneni; Sherly Sebastian; Kent A Heck; J Clay Goodman; Shankar P Gopinath; Zhandong Liu; Ganesh Rao; Sharon E Plon; Daniel Yoshor; David A Wheeler; Huda Y Zoghbi; Tiemo J Klisch Journal: Proc Natl Acad Sci U S A Date: 2019-10-07 Impact factor: 11.205
Authors: Pranay Soni; Mark A Davison; Jianning Shao; Arbaz Momin; Diana Lopez; Lilyana Angelov; Gene H Barnett; Joung H Lee; Alireza M Mohammadi; Varun R Kshettry; Pablo F Recinos Journal: J Neurooncol Date: 2020-11-17 Impact factor: 4.130
Authors: Naureen Keric; Darius Kalasauskas; Christian F Freyschlag; Jens Gempt; Martin Misch; Alicia Poplawski; Nicole Lange; Ali Ayyad; Claudius Thomé; Peter Vajkoczy; Bernhard Meyer; Florian Ringel Journal: J Neurooncol Date: 2020-01-03 Impact factor: 4.130
Authors: Wenya Linda Bi; Lakshmi Nayak; David M Meredith; Joseph Driver; Ziming Du; Samantha Hoffman; Yvonne Li; Eudocia Quant Lee; Rameen Beroukhim; Mikael Rinne; Ricardo McFaline-Figueroa; Ugonma Chukwueke; Christine McCluskey; Sarah Gaffey; Andrew D Cherniack; Jennifer Stefanik; Lisa Doherty; Christina Taubert; Meghan Cifrino; Deborah LaFrankie; Thomas Graillon; Patrick Y Wen; Keith L Ligon; Ossama Al-Mefty; Raymond Y Huang; Alona Muzikansky; E Antonio Chiocca; Sandro Santagata; Ian F Dunn; David A Reardon Journal: Neuro Oncol Date: 2022-01-05 Impact factor: 12.300